• Compugen posted a Q2 GAAP net loss of USD 7.01 million, narrowing from USD 7.34 million a year earlier.
• Revenue more than doubled to USD 2.6 million, reflecting recognition of Gilead upfront and IND milestone payments.
• R&D expenses rose 11.8% to USD 6.31 million, while G&A spending edged up to USD 2.26 million.
• Cash and cash-related balances totaled about USD 125.3 million at June 30, with runway expected to fund operations into 2029.
• MAIA-ovarian interim analysis for COM701 remains on track, with median progression-free survival data expected by Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608030700PR_NEWS_USPR_____LN17303) on August 03, 2026, and is solely responsible for the information contained therein.